Walker R, Crebbin V, Stern J, Scudder S, Schwartz P
Ciba-Corning Diagnostics Corp., Alameda, CA 94502.
Anticancer Res. 1994 Sep-Oct;14(5A):1703-9.
Urinary gonadotropin peptide (UGP) was measured in 866 urines from normal women and women with benign and malignant gynecologic disease using the Triton UGP enzyme immunoassay. The greatest level of overexpression of the marker was observed in patients with ovarian cancer. Using a cutoff of 4 fmol/mg creatinine, UGP was overexpressed in samples from 2% of normal premenopausal women, 15% of normal postmenopausal women, 5% of women with benign gynecologic disease, and 59% of women with ovarian cancer. UGP expression was independent of the histologic type of ovarian cancer. The expression of UGP and CA 125 were not correlated and use of the two markers in tandem increased the sensitivity of detection of disease by greater than 20% over that which was observed using each marker individually. UGP levels were correlated with clinical status, and doubled in value in 67% of patients with progressive disease, and were halved in 93% of patients who were in remission at the time of the study.
采用Triton UGP酶免疫分析法对866名正常女性以及患有良性和恶性妇科疾病的女性的尿液进行了尿促性腺激素肽（UGP）检测。在卵巢癌患者中观察到该标志物的过表达水平最高。以4 fmol/mg肌酐为临界值，UGP在2%的正常绝经前女性、15%的正常绝经后女性、5%的患有良性妇科疾病的女性以及59%的卵巢癌女性的样本中过表达。UGP的表达与卵巢癌的组织学类型无关。UGP和CA 125的表达不相关，联合使用这两种标志物比单独使用每种标志物时疾病检测的灵敏度提高了20%以上。UGP水平与临床状态相关，在67%病情进展的患者中其值翻倍，在研究时处于缓解期的患者中有93%其值减半。
